GLUCOCORTICOIDS AND RHEUMATOID ARTHRITIS

Zhdan V. M., Volchenko H. V., Babanina M. Y., Tkachenko M. V., Khaimenova H. S.

LITERATURE REVIEWS

Scentific article

Glucocorticoids (GCs) remain an important component of controlling the activity of rheumatoid arthritis (RA). If there is an opportunity to be treated with modern disease-modifying antirheumatic drugs, which compare favorably with the speed of achieving a therapeutic effect, short-term GCs administration can be useful and safe, although many specialists are restrained in this approach. International recommendations emphasize the indisputable benefit of GCs at the beginning of treatment, as well as during an exacerbation, but taking into account the minimum effective cumulative dose due to a wide range of potential side effects. Most medical practitioners prefer a dose of methylprednisolone 8 mg per day for a duration of 3 to 6 months, however, it is possible to vary the duration of the appointment and the dose depending on the needs of a particular clinical situation. Almost always, GCs ensure the success of treatment at the onset, as well as during episodes of exacerbation of RA, however, adherence to the safety principles and a careful assessment of the benefit-risk ratio for the patient is always necessary. Despite the reasonable optimism, one should not forget about the toxic effects of GCs, especially when used in moderate and high doses, especially over a long period of time. In addition, even low doses of GCs can have undesirable effects. The long-term safety of GCs may be related to the cumulative dose, and in addition to the daily dose, duration is also critical. GCs should be used in the minimum effective dose and for the shortest possible time. Most studies evaluated the efficacy of GCs as a “bridge therapy” in combination with different groups of traditional and modern basic drugs. Thus, existing studies are mainly focused on patients with RA onset, while data on RA with a long history is clearly insufficient. However, GC is also effective in this population for exacerbation control. If long-term, more than 6 months of GCs therapy is required, EULAR recommends a dose of 5 mg (as prednisolone) per day or less (if this is sufficient to control the disease). GCs monotherapy is not the optimal therapeutic approach, despite its low cost, and their potential in combination with methotrexate to reduce or delay the need for the use of modern effective biological and targeted basic agents.

glucocorticoids, rheumatoid arthritis, disease-modifying antirheumatic drugs, “bridge therapy”.

1. Zhdan VM, Volchenko GV, Kitura ОY, Ваbаnіnа МY, Shylkina LM, Tkachenko MV. Problemy revmatychnykh zakhvoriuvan u praktytsi simeinoho likaria. Rannii diahnoz і likuvannia: navchalnyi posibnyk. Poptava: ASMI; 2013. 250 s. [in Ukrainian].
2. Zhdan VM, Ivanickiy IV, Shtompel VY, Zazykina DS, Lebid VH. Problemy revmatychnykh zakhvoriuvan u praktytsi simeinoho lіkаrіа. Zahalni pytannia: navchalnyi posibnyk. Poptava: ASMI; 2013. 208 s. [in Ukrainian].
3. Kovalenko VM, Shuba NM, redaktor. Natsionalnyi pidruchnyk z revmatolohii. Kyiv: MORION; 2013. 672 s. [in Ukrainian].
4. Svintsitskyi AS. Diahnostyka ta likuvannia revmatychnykh zakhvoriuvan: navchalnyi posibnyk. Kyiv: Vydavnychyi dim Medknyha; 2017. 372 s. [in Ukrainian].
5. Kovalenko VM, Shuba NM, redaktor. Nomenklatura, klasyfikatsiia, kryterii diahnostyky ta pryntsypy likuvannia revmatychnykh khvorob. Kyiv; 2004. 156 s. [in Ukrainian].
6. Kovalenko VM, Shuba NM, redaktor. Nomenklatura, klasyfikatsiia, kryterii diahnostyky ta pryntsypy likuvannia revmatychnykh khvorob. Kyiv; 2004. 156 s. [in Ukrainian].
7. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76:948-59.
8. Daien CI, Hua C, Combe B, Landewe R. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review. Informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open. 2017;3:e000404.
9. Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies RMD Open. 2020;6:e000536.
10. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1-26.
11. 1Black RJ, Lester S, Buchbinder R, Barrett C, Lassere M, March L, et al. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res Ther. 2017;19.
12. Pincus T, Sokka T, Castrejón I, Cutolo M. Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken). 2013;65:729-36.
13. Makol A, Davis JM 3rd, Crowson CS, Therneau TM, Gabriel SE, Matteson EL. Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort, 1980-1994 versus 1995-2007. Arthritis Care Res (Hoboken). 2014;66:1482-8.
14. Albrecht K, Callhoff J, Schneider M, Zink A. High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. Rheumatol Int. 2015;35:1377-84.
15. Roubille C, Rincheval N, Dougados M, Flipo RM, Daurès JP, Combe B. Seven-Year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann Rheum Dis. 2017;76:1797-802.
16. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review. Informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1102-7.
17. Alten R, Grahn A, Holt RJ, Rice P, Buttgereit F. Delayed-Release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. RMD Open. 2015;1:e000134.
18. Stouten V, Joly J, De Cock D, Pazmino S, Van der Elst K, Westhovens R, et al. Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years [abstract]. Arthritis Rheumatol. 2017;69(10).
19. Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, et al. Long-Term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med. 2016;164:523-31.
20. Safy M, Jacobs J, IJff ND, Bijlsma J, van Laar JM, de Hair M. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 Mg prednisone daily: follow-up after the second computer-assisted management in early rheumatoid arthritis trial. Ann Rheum Dis. 2017;76:1432-5.
21. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156:329-39.
22. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I. Low-dose prednisolone in addition to the initial diseasemodifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52:3360-70.
23. Hafström I, Albertsson K, Boonen A, van der Heijde D, Landewé R, Svensson B. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis. 2009;68:508-13.
24. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010;62:2852-63.
25. van Tuyl LH, Boers M, Lems WF, Landewé RB, Han H, van der Linden S, et al. Survival, comorbidities and joint damage 11 years after the cobra combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010;69:807-12.
26. Choy EH, Kingsley GH, Corkill MM, Panayi GS. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the introduction phase of chrysotherapy. Rheumatology. 1993;32:734-9.
27. de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73:1331-9.
28. Hetland ML, Østergaard M, Ejbjerg B, Jacobsen S, Stengaard-Pedersen K, Junker P, et al. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Ann Rheum Dis. 2012;71:851-6.
29. Menon N, Kothari SY, Gogna A, Sharma R. Comparison of intra-articular glucocorticoid injections with DMARDs versus DMARDs alone in rheumatoid arthritis. J Assoc Physicians India. 2014;62:673-6.
30. Ravindran V, Rachapalli S, Choy EH. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatology. 2009;48:807-11.
31. Ajeganova S, Svensson B, Hafström I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4:e004259.
32. Santiago T, da Silva JAP. Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. Ann N Y Acad Sci. 2014;1318:41-9.
33. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-9.
34. del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014;66:264-72.

«Bulletin of problems biology and medicine» Issue 4 (158), 2020 year, 17-23 pages, index UDK 616.72-002.77-085

10.29254/2077-4214-2020-4-158-17-23